The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) ...

Tiziana Life Sciences (TLSA) announced dosing has commenced at Johns Hopkins University, JHU, Autoimmunity Center of Excellence, the third ...

The trial aims to evaluate the antibody’s efficacy in treating non-active secondary progressive multiple sclerosis.

Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New Drug application to the U.S. FDA for the mid-stage trial of intranasal ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana Life Sciences (NASDAQ:TLSA) recently announced that it submitted its IND of fully human anti-CD3 monoclonal antibody foralumab to begin a phase 2 study for the treatment of patients with ...

A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with ...

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...